# Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

> **NCT04928222** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SkinJect, Inc.** · enrollment: 25 (estimated)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Doxorubicin-containing MNA
- **DRUG:** Placebo-containing MNA

## Key facts

- **NCT ID:** NCT04928222
- **Lead sponsor:** SkinJect, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-24
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04928222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04928222, "Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04928222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*